Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Blood (2024) 144 (19): 1993–2001.

https://doi.org/10.1182/blood.2024024657

Published: 2024

Includes: Supplemental data

Journal Articles

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Blood (2024) 144 (Supplement 1): 476.

https://doi.org/10.1182/blood-2024-201218

Published: 2024

Journal Articles

Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

Blood (2023) 142 (Supplement 1): 4641.

https://doi.org/10.1182/blood-2023-181595

Published: 2023

Journal Articles

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Blood (2023) 142 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2023-181541

Published: 2023

Journal Articles

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Blood (2023) 142 (Supplement 1): 865.

https://doi.org/10.1182/blood-2023-172583

Published: 2023

Journal Articles

Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study

Howland E. Crosswell, MD, Ann S. LaCasce, MD MSc, Nancy L. Bartlett, MD, David J. Straus, MD, Kerry J Savage, BSc, MD MSc, Keenan Fenton, Gerald Engley, PharmD, Hina Jolin, Pharm D, Rachael Liu, PhD, Pier Luigi Zinzani, MD, Graham P. Collins, MB BS DPhil, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD

Blood (2018) 132 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2018-99-112907

Published: 2018

Journal Articles

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Blood (2018) 132 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2018-99-112178

Published: 2018

Journal Articles

Cyclosporin Dosing and Toxicity Following Allogeneic Haematopoietic Stem Cell Transplant at Austin Health

Danielle H Robinson, Charlotte Hughes, BBiomedSci, MD, Simon Zhao-Xiong He, MBBS, FRACP, FRCPA, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD

Blood (2018) 132 (Supplement 1): 5701.

https://doi.org/10.1182/blood-2018-99-116146

Published: 2018

Journal Articles

Nivolumab for Relapsed or Residual Haematological Malignancies after Allogeneic Haematopoietic Stem Cell Transplantation (NIVALLO)

Eric Wong, MBBS, Emily Dawson, Joanne Davis, PhD, Rachel Koldej, PhD, Mandy Ludford-Menting, Matthew Lansdown, Heather Lambie, Jeffrey Szer, MBBS, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, David Ritchie, MBChB, PhD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 4633.

https://doi.org/10.1182/blood-2018-99-112310

Published: 2018

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Blood (2018) 132 (Supplement 1): 459.

https://doi.org/10.1182/blood-2018-99-110569

Published: 2018

Journal Articles

Urine Cultures at the Onset of Febrile Neutropenia (FN) in Patients with Haematological Malignancies Rarely Impact Antibiotic Management in the Absence of Urinary Symptoms

Sam Grigg, BSc, Patrick Date, BSc, Eliza A Hawkes, FRACP, MBBS, Douglas Johnson, MBBS, PhD FRACP, Zoe Loh, MBBS, Ortis Estacio, MD, Andrew P Grigg, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 3435.

https://doi.org/10.1182/blood.V130.Suppl_1.3435.3435

Published: 2017

Journal Articles

Comparison of Frontline Induction Therapy Using Idarubicin in Combination with High-Dose (HDAC3) Versus Intermediate-Dose Cytarabine (IDAC3) in Adult Acute Myeloid Leukemia

Ing Soo S Tiong, MBBS, Katherine Fielding, MBBS, BMedSci, Chun Y Fong, MBBS, BMedSci, FRACP,FRCPA, Hadley Bortz, BPharm, GradCert PharmPrac, MClinPharm, MSHP, Sharon Avery, MBBS, FRACP, FRCPA, Andrew P Grigg, MBBS, MD FRACP, FRCPA, Andrew Wei, MBBS, PhD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 3868.

https://doi.org/10.1182/blood.V130.Suppl_1.3868.3868

Published: 2017

Journal Articles

A Multicenter Retrospective Review of Outcomes of Diffuse Large B Cell Lymphoma (DLBCL) in the Elderly Treated with RCHOP in Australia

Michael D Ashby, MBBS, Eliza A Hawkes, FRACP, MBBS, Andrew P Grigg, MBBS, MD FRACP, FRCPA, Grace Gard, MBBS, Zi Yun Ng, MBBS, Huayi Ellen Huang, Chan Yoon Cheah, Zoe Loh, MBBS, Allison Mo, MD, Geoff Chong, MD, Andrew B M Lim

Blood (2017) 130 (Supplement 1): 4143.

https://doi.org/10.1182/blood.V130.Suppl_1.4143.4143

Published: 2017

Journal Articles

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

David M Ross, MBBS, PhD FRACP, FRCPA, Ilaria S Pagani, PhD, Naranie Shanmuganathan, MBBS, John F Seymour, MBBS, PhD, Anthony K Mills, FRACP, FRCPA, MBBS, Robin J Filshie, PhDFRACP,FRCPA, Christopher K Arthur, MDFRACP,FRCPA,MBBS, Phuong Dang, Verity A Saunders, Jody Braley, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Deborah L White, PhD FFSc (RCPA), Andrew P Grigg, MBBS, MD FRACP, FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Susan Branford, PhD, Timothy P. Hughes, MD

Blood (2017) 130 (Supplement 1): 1597.

https://doi.org/10.1182/blood.V130.Suppl_1.1597.1597

Published: 2017

Journal Articles

Routine Blood Investigations Have Limited Utility in Routine Surveillance of High-Grade Lymphomas (HGL) in Remission after First-Line Therapy

Zoe Loh, Leigh Beveridge, MBBS, Andrew P Grigg, MBBS MD, Ortis Estacio, Geoff Chong, MD, Francis Ha, Michael Gilbertson, Eliza A Hawkes

Blood (2016) 128 (22): 3040.

https://doi.org/10.1182/blood.V128.22.3040.3040

Published: 2016

Journal Articles

Cerebral Toxoplasmosis in a Patient with Prolonged CD4 Lymphopenia Post Autologous Haematopoietic Stem Cell Transplant

Arielle van Mourik, MBBS BBiomedSci, Andrew P Grigg, MBBS MD

Blood (2016) 128 (22): 4902.

https://doi.org/10.1182/blood.V128.22.4902.4902

Published: 2016

Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Blood (2015) 126 (23): 815.

https://doi.org/10.1182/blood.V126.23.815.815

Published: 2015

Journal Articles

Evaluation of Pharmacokinetic-Based Dose Predictions of High Dose Melphalan in Patients with Myeloma

Judith Trotman, MBChB, Peter J. Shaw, MBBS, MA, FRACP, Campbell Tiley, MBBS,FRACP, FRCPA, Sundra Ramanathan, MBBS FRCPA FRACP, Andrew P Grigg, MBBS MD, Stephen Robert Larsen, MBBS PhDFRCPA FRACP, Peter Presgrave, MBBS, PhD FRACP, FRCPA, Yiu-Lam Kwan, MBBS, FRACP, FRCPA, Elizabeth Newman, RN, Christa Nath, BSC (Hons), PhD

Blood (2015) 126 (23): 4314.

https://doi.org/10.1182/blood.V126.23.4314.4314

Published: 2015

Journal Articles

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine Tam, MBBS, MD, Andrew P Grigg, MBBS MD, Stephen Opat, MBBS, Matthew Ku, MBBS, Michael Gilbertson, MBBS, Mary Ann Anderson, MBBS, John F. Seymour, MBBS, PhD, David S. Ritchie, MDPhD, Carmen Dicorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, PhD, Lusong Luo, Ling Xue, Andrew W. Roberts, MBBS, PhD

Blood (2015) 126 (23): 832.

https://doi.org/10.1182/blood.V126.23.832.832

Published: 2015

Journal Articles

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Blood (2015) 125 (6): 915–923.

https://doi.org/10.1182/blood-2014-07-590315

Published: 2015

Includes: Supplemental data

NARROW

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study

Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study

Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Cyclosporin Dosing and Toxicity Following Allogeneic Haematopoietic Stem Cell Transplant at Austin Health

Nivolumab for Relapsed or Residual Haematological Malignancies after Allogeneic Haematopoietic Stem Cell Transplantation (NIVALLO)

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Urine Cultures at the Onset of Febrile Neutropenia (FN) in Patients with Haematological Malignancies Rarely Impact Antibiotic Management in the Absence of Urinary Symptoms

Comparison of Frontline Induction Therapy Using Idarubicin in Combination with High-Dose (HDAC3) Versus Intermediate-Dose Cytarabine (IDAC3) in Adult Acute Myeloid Leukemia

A Multicenter Retrospective Review of Outcomes of Diffuse Large B Cell Lymphoma (DLBCL) in the Elderly Treated with RCHOP in Australia

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

Routine Blood Investigations Have Limited Utility in Routine Surveillance of High-Grade Lymphomas (HGL) in Remission after First-Line Therapy

Cerebral Toxoplasmosis in a Patient with Prolonged CD4 Lymphopenia Post Autologous Haematopoietic Stem Cell Transplant

Evaluation of Pharmacokinetic-Based Dose Predictions of High Dose Melphalan in Patients with Myeloma

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only